anti-EpCAM-AAV2 + shEGFR

A combination **gene therapy platform** consisting of a modified adeno-associated virus serotype 2 (**AAV2**) vector conjugated to an anti-EpCAM antibody for tumor targeting, and encoding a short hairpin RNA (**shRNA**) that silences epidermal growth factor receptor (**EGFR**) expression. The anti-EpCAM antibody directs the viral vector to **EpCAM-positive tumor cells**, enabling tumor-specific delivery. Upon systemic administration, the vector delivers shEGFR to tumor cells for **long-term EGFR knockdown**, leading to **inhibition of tumor growth** in EpCAM+ cancers (e.g., ovarian cancer). The construct utilizes a **streptavidin-biotin bridge** for conjugation and demonstrates enhanced selectivity for tumor tissue and reduced off-target effects. This agent is experimental and has not been approved for clinical use[1].

Other names

anti-EpCAM antibody-conjugated AAV2/shEGFRanti-EpCAM-AAV2/shEGFR vector